Close Menu

NEW YORK ─ Proteomics International Laboratories said Thursday it has secured the CE mark for its PromarkerD Immunoassay (IA) kit, which is part of the PromarkerD test system already available in Europe for predicting the onset of kidney disease in patients with type 2 diabetes.

The Perth, Australia-based firm said PromarkerD (IA) is a high-throughput version of PromarkerD (MS), its CE marked predictive diagnostic test for diabetic kidney disease that uses mass spectrometry.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.